Interventions that improve childhood health directly improve the quality of life and, in addition, have multiplier effects, producing sustained population and economic gains in poor countries. We suggest how contemporary global institutions shaping the development, pricing and distribution of vaccines and drugs may be modified to deliver large improvements in health. To support a justice argument for such modification, we show how the current global economic order may contribute to perpetuating poverty and poor health in less-developed countries.
Introduction
Our approach is conditioned by three factors. First, the global burden of disease is largely borne by poor countries. Second, within poor countries, it is largely borne by children. Third, poverty heightens the risk of contracting disease and childhood exposure to disease causes poverty in later life and, plausibly, into the next generation.
The first factor may suggest that improving global health is essentially the duty of poorcountry governments, but we present ethical and economic arguments against this view. The second and third factors suggest that health interventions may be self-financing and self-sustaining within the span of a generation and, overall, not only intrinsically desirable but also cost-effective.
However, commitment problems arise in achieving international coordination of interventions and these are enhanced by the fact that some costs of inaction flow in an intergenerational frame (familiar from debates about climate change). This motivates consideration of global institutional reforms focused on alleviating disease burdens borne by children and especially by girls.
We suggest how contemporary global institutions shaping the development, pricing and distribution of vaccines and drugs may be modified to deliver large improvements in health. We show how interventions that improve childhood health directly improve the quality of life and, in addition, have multiplier effects, producing long-term population and economic gains in poor countries. They also tend to generate positive spillovers for richer countries through reductions in population growth, migration, pollution, and the externalities of infectious disease. To support a justice argument for such modification, we show how the current global economic order may contribute to perpetuating poverty and poor health in developing countries. We argue that millions of poor people are caught in a poverty-disease "trap", the origins of which are typically in their early childhood and, indeed, their parents' childhood. This suggests an explanatory role for past global institutions, in which slavery and colonial rule loom large.
Recent estimates suggest that the gains in life expectancy in the United States over the 20 th century were worth more than $1.2 million per person to the current population (Murphy and Topel 2005) . If we allow for the intrinsic value of life, for the longer horizon of life for children (as opposed to adults) saved from death, for next generation effects, and for socioeconomic gains from health, then the benefits for poor countries are possibly larger. Moreover, the costs of prevention and cure are likely lower in poor countries where great health gains can still be achieved by evidencebased interventions such as provision of clean water, micronutrients, oral rehydration therapy, insecticide-treated bed nets, vaccines and generic antibiotics, that are much cheaper than addressing the diseases (e.g., cancer and diabetes) prevalent in richer countries today.
The gap in life expectancy between rich and poor countries is today about thirty years.
Someone born in Sierra Leone is about 87 times as likely to die in childhood as someone born in Sweden. Between 1850 and 1950, most high-income countries experienced historically unprecedented mortality declines, which raised life expectancy at birth by nearly thirty years. Most of these gains stemmed from the control of infectious disease in children. Today less than 1% of all deaths in richer countries are of children under the age of five, while child deaths still dominate mortality in poorer countries (Cutler et al. 2006) . Some 7.6 million children are dying each year before they turn five (www.unicef.org/media/media_59795.html) and avoidably so (Jones et al. 2003) . The knowledge (e.g., concerning sanitation) and innovations (e.g., antibiotics) that were successful in richer countries are now available to poorer countries. Yet, in poorer countries only about 20% of children have access to safe water and only 20% of children who need antibiotics to treat pneumonia receive them (WHO 2010).
The costs of adequate nutrition and treatment are too small for poverty alone to explain the persistence of high levels of disease (Deaton 2007) . But because poverty is a major contributor to morbidity and mortality, it is pertinent to note that the world poverty problem, which is so unimaginably large in human terms, is small in economic terms. In 2005, the shortfall of the world's poor from an adequate standard of living amounted to about 2 percent of global household income or 1.2 percent of world income (the sum of all gross national incomes).
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In this essay we underline the role of a global political economy in generating significant barriers to improvements in both disease and poverty.
This global poverty gap could have been filled almost twice over, just from the gain in the share of the richest ventile during 1988-2005 (Section 3 below). The widespread poverty we see today is largely avoidable.
The relevance of political factors at the national level is widely recognized. Foreign aid to the developing world is often characterized as being captured or dissipated by corrupt or failed governments (Temple 2010: section 7) . What is relatively unrecognized is the bearing of the broader international political economy upon this state of affairs and, further, on the shape of global institutional arrangements as they pertain to disease and poverty. Even where democratic, governments that have signed up to international agreements do not necessarily represent the preferences of their people. For these reasons, we suggest here a reconsideration of the current institutional order, focusing upon aspects that impinge upon health. The preservation of human rights provides an excellent starting point but we underline that this is a domain in which pursuit of this goal is compatible with widespread and lasting human and economic gains.
The essay is structured as follows. Section 2 pulls together new evidence from epidemiology and economics that illustrates relevant causal pathways and demonstrates the costs of failing to intervene. This evidence demonstrates complementarities between improvements in early-life health and cognitive attainment, the effectiveness of both in raising living standards, and the significance of investments in girls for breaking the intergenerational persistence of ill health and poverty. Section 3 argues that richer countries have not only the incentives to contribute to disease mitigation in poorer countries but also an active moral responsibility to do so. Section 4 concludes.
Hidden and Long-Term Returns to Disease Mitigation
This section argues that mitigating infectious disease in poor countries and providing all children with a healthy start will bring about continued gains and convergence in health and socioeconomic status across the lifespan of the exposed generation and the next. Much of the literature on socioeconomic inequality in early childhood or equality of opportunity at birth focuses upon the influence of parental resources and attitudes on investments in children (Black et al., 2007; Cunha and Heckman, 2009 ). We highlight evidence from new work focusing on the importance of early-life health (Currie, 2009; Almond and Currie, 2011) . 
Infectious Disease: the Importance of Childhood
The effect sizes in this literature are large enough to suggest that interventions against infectious disease (effectively targeting infant health) may be more effective at raising educational performance and income in poor countries than conventional interventions such as reducing class size (Miguel and Kremer, 2004; Kremer and Holla 2009) .
Prioritizing the health of girls (widely disadvantaged today) can further enhance these long-term benefits because mothers are pivotal in the intergenerational transmission of health (Bhalotra and Rawlings, 2010) . We now develop these arguments in a natural sequence.
The primary proximate cause of death in poor countries is infectious disease. Pneumonia, HIV/AIDS, diarrhea, tuberculosis and malaria exert the largest toll. Under-nutrition lowers 2 We provide relevant examples rather than a comprehensive survey of this literature.
resistance to infectious disease which in turn aggravates under-nutrition (Black et al. 2003 , Jones et al. 2003 . 
Chronic Disease
Young children are especially vulnerable because their immune systems are immature and because the metabolic cost of nutritional deprivation is especially large in the peak years of human growth. Many children die. Others survive, assisted by adaptive physiological changes such as reduced body size and altered kidney morphology. Recent research suggests that this short-term thrift may however exert a penalty in the longer run, making survivors of childhood disease more likely to contract chronic diseases like cancer, cardiovascular problems and diabetes later (Barker 1997, Almond and Currie 2011) . These adverse effects are thought to be larger when, as in many developing countries, the nutritional environment is changing over the life course.
The "Barker hypothesis" [above] suggests that the emergence of chronic diseases in poor countries may be aggravated by infectious disease exposure fifty to sixty years ago. This is when many of these countries were still under colonial rule or just emerging from it Brain development consumes a very large share of metabolic resources in early life (85% compared with 25% in adults), and resource deprivation therefore endangers cognitive development (Eppig, Fincher and Thornhill 2010 , Bharadwaj and Neilson 2011 , Bhalotra, Miranda and Venkataramani 2012 . Moreover, there is evidence suggesting (a) the productivity of investments in an individual's health and education is lower when the endowments that they start out with are weaker, and (b) investments in health and education are mutually reinforcing (Cunha and Heckman, 2007; Glewwe and Miguel, 2008) . Related evidence shows that increases in life expectancy stimulate increased investments in education, consistent with the returns to education flowing over a longer 3 There are two mechanisms for the latter. First, the immune response generated to fight infection is resource-intensive and taxes available nutritional resources (Crimmins and Finch 2004) . Second, infectious disease tends to moderate appetite and to inhibit assimilation of nutrition (Scrimshaw, Taylor and Gordon 1968) . 4 Recent research in economics shows persistent impacts of slavery and colonial institutions on a range of contemporary outcomes including inequality, economic growth and polygamy (Sacerdote 2005 , Acemoglu et al. 2001 , Fenske 2011 horizon. This is nicely illustrated by Jayachandran and Lleras-Muney (2010) , showing that a sharp drop in maternal mortality in Sri Lanka stimulated investment in the education of girls. This causal chain runs across generations in an endogenous process that may be characterized as a poverty trap in which ill health is the primary mechanism (Currie and Moretti 2007 , Bhalotra and Rawlings 2010 . By their nature, poverty traps call for external intervention as there is no evident spontaneous mechanism by which they dissipate (Bonds et al. 2010 ).
There is widespread recognition that poverty leads to ill health (Gwatkin et. al. 2000, Friel and Marmot 2011) . It is less widely known that ill health leads to poverty (or that health-promoting interventions produce educational and income gains). 
Health Inequalities and Institutional Design
One reason for this is that long-range longitudinal data is scarce and the causal impact of health on income or poverty takes time to emerge (the time from early childhood to employment or child rearing). Another reason is the difficulty of identifying causality when the relationship runs in both directions and is subject to confounders. Recent studies address this challenge. A twenty-year follow-up of a randomized control trial involving de-worming in Kenyan schools estimates that treatment generated 2-3 additional years of schooling and a 21-29% increase in income (Baird et al., 2011) . Other studies using cohort data on large-scale historical health interventions arrive at remarkably similar estimates.
Bleakley (2010) estimates that malaria eradication in the Americas increased wage income by 15-27%, and Bhalotra and Venkataramani (2011) estimate that the 30% drop in pneumonia mortality after the introduction of antibacterials was associated with a 19% income gain for survivors exposed to the disease in infancy.
Because infectious diseases are more prevalent amongst the poor, their prevention and cure reduce health and thereby socioeconomic inequalities. However, the design of institutions mediates this process. Here we present some compelling illustrations from recent US history, which are of generic relevance to our central thesis: that the full benefit of other changes (such as rising incomes in developing countries) may depend upon institutional change (or, the lifting of institutional barriers to access and opportunity).
Pneumonia was the leading cause of death in the early 1930s, twice as prevalent among (poorer) African-Americans as among whites. In both populations, infection rates were highest amongst infants. Upon the introduction in 1937 of sulfonamides, the first antibiotics, pneumonia fell sharply in both populations, but the absolute health gain for blacks was larger, in line with their higher pre-intervention exposure levels. Using econometric methods that isolate the impact of reduced pneumonia exposure in infancy on later life outcomes, we find that the education and incomes of whites benefited enormously from being born just after 1937 as compared with just before, but post-sulfa African-American cohorts exhibited no similar gains. We argue that these race disparities arise from blacks facing more limited opportunities and incentives to invest in quality education and employment in the pre-Civil Rights era (Bhalotra and Venkataramani, 2011) . Returns to educational investments amongst blacks were capped by school segregation. Black schools were of consistently lower quality than white schools (Card and Krueger, 1992) . The results for whites illustrate how effectively interventions that improve early-life health can produce socio-economic gains while the results for blacks illustrate how this translation may be inhibited by institutional barriers to education and the labor market.
Some thirty years later, Title VI of the 1964 Civil Rights Act, mandating desegregation in institutions receiving federal funds, provided a further positive shock to health endowments specifically of African-Americans. Integration of hospitals led to a substantial narrowing of the racial gap in post-neonatal infant mortality (Almond and Chay, 2007) . Recent evidence shows how the dismantling of institutional barriers to early-life health care was a key driver of the improved test performance of black teenagers in the 1980s and stimulated race convergence in cognitive development and earnings (Chay, Guryan and Mazumder, 2009 ).
The Intergenerational Transmission of Health
The previous subsection outlines compelling evidence that childhood health interventions lead not only to immediate reductions in morbidity and mortality amongst children, but also to health and socioeconomic gains in adulthood, which in turn raise the health and subsequent socioeconomic status of their children. In this way the benefits of a one-off intervention today persist into the future. For instance, girls exposed to the Great Chinese Famine grew up to have less healthy children (Fung and Wei 2010) , and girls born into conditions of high infant mortality have children less likely to survive infancy (Bhalotra 2010) . Mother-child transmission of health tends to be stronger than father-child, and a focus on erasing gender disparities in child health is then supported by efficiency as well as equity considerations (Bhalotra and Rawlings 2010 and references there). Immunization programs, as much as economic growth, have been shown to attenuate the intergenerational transmission of health at the low end of the maternal health distribution (Bhalotra and Rawlings forthcoming) -yet girls are routinely less likely to be immunized in many poor countries (Oster 2009, Bharadwaj and Nelson 2010) . This evidence further strengthens the case for early-life health interventions and their initial targeting at girls.
Health Interventions and Population Growth
Health interventions may influence population growth through three channels. The first is direct, by lowering mortality. The other two operate through fertility (Galor and Weil 1996 , Galor 2010 , Bhalotra and van Soest 2008 and migration (Mesnard and Seabright 2009) . Fertility may be expected to respond to the mother's health endowment and to changes in the health and survival prospects of potential offspring. Fertility declined just after the early twentieth century eradication of hookworm in the US South and the large-scale antibiotic treatment of pneumonia, possibly because parents were substituting "quality" for "quantity" of children Lange 2009, Bhalotra, Hollywood and . The 1991 clean water reform in Mexico, which sharply reduced morbidity and mortality from diarrhea, also led to a decline in fertility (Bhalotra and Venkataramani 2011b) . The tendency for mothers to have fewer births once their (potential) offspring become more likely to thrive suggests a pathway from disease mitigation to lower population growth and more rapid economic growth (Galor and Weil 2000) .
In subsection 2.3, we highlighted evidence of causal links flowing from improvements in early-life health to cognitive development, education and earnings. In subsection 2.5, we highlighted evidence that investments in the early-life health of women are particularly fecund as they produce returns in the second generation. Drawing also on the evidence regarding fertility, we conclude that investments in child and especially girl health promise massive and lasting health and socioeconomic gains as well as social changes that enable women to make productive contributions beyond childbearing.
The Globalization of Disease
Human alteration of ecosystems in the processes underlying economic growth (e.g., urbanization, irrigation, deforestation) facilitates the emergence and spread of infectious diseases. 
Health, Justice and Global Institutions
Building upon the empirical insights outlined in Section 2, this Section argues that richer countries have an active moral responsibility to contribute to mitigating the disease burden in poor countries, based on their contribution, through global institutional design, to the persistence of the poverty-disease cycle in the developing world.
Patents and Drug Prices
As disease is growing increasingly globalized, so is the management of disease. One central component of globalization has been the creation of an increasingly dense and influential supranational system of rules and actors that shape and regulate not only the ever-growing share of interactions that traverse national borders but also purely domestic interactions, profoundly shaping, for instance, trade, investment, innovation, working conditions, environmental protection, and the availability of weapons. In particular, the 1994 TRIPS Agreement, created with the World Trade Organization (WTO), has shifted important rules governing the development and sale of medicines from the national to the global level.
The TRIPS Agreement entitles pharmaceutical firms to protect their innovations with twenty-year product patents, which enable them to suppress generic competition. 7 This has raised the prices of new medicines in the developing world to many times the marginal cost of production, thereby making many treatments inaccessible to those who need them most.
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A common defense of TRIPS is that the manufacture and sale of generic products are moral crimes ("theft", "counterfeiting", "piracy") that any just legal system ought to suppress (Nozick 1974:182) . But the defenders of this view have not managed to provide a convincing argument to show why the fact that one person has made a new product should give her a natural right to bar others from making a like product out of their own raw materials (Hollis and Pogge: Chapter 5).
Patents fit poorly with libertarian views which celebrate property rights and freedom since they restrict the freedom to use one's physical property in novel ways.
Another defense states that poor countries signed the TRIPS Agreement voluntarily. But many had little understanding of its implications at the time and they needed the improved access to rich country markets that was then offered in return. The interests of the poor majority were often given little weight in the deliberations of those who held political power in less-developed countries (Chapter 24 below).
In view of the difficulty of formulating convincing appeals to natural law or informed consent, most TRIPS defenders resort to pragmatic arguments stressing the need for economic incentives. The proposition is that potential innovators will develop new medicines only if this can earn them a decent return on their investment (WTO 2012); and such medicines, while immediately benefiting only the rich, will eventually go generic and then benefit poor patients as well. A weakness of this argument is that, by the time a medicine goes generic, its effectiveness may have been eroded by microbial adaptation or other changes. Another, neglected drawback is the long-term cost of the delay arising from the intergenerational effects of poor childhood health (Section 2).
7 "TRIPS" stands for Trade-Related Aspects of Intellectual Property Rights. The TRIPS Agreement resulted from strong lobbying by the agribusinesses, pharmaceutical, entertainment and software industries. Product patents allow patentees to veto the manufacture and sale of a patented molecule regardless of how it is produced. Before TRIPS, India granted only process patents, which allow patentees to veto merely a specific way of making a molecule. India is the leading supplier of medicines in the less-developed countries. See WHO 2011 and Chapter 24 below. 8 Parallel-import and reference-pricing problems notwithstanding, pharmaceutical firms often find it profitable to sell their patented products in poorer countries at lower prices. But intra-national inequalities tend to be so large that in most less-developed countries an important medicine's domestically profitmaximizing sales price will place it out of reach of the majority of the country's population (Flynn, Hollis and Palmedo 2009) .
Despite these problems, the status quo might be defensible if the development of important new medicines could be stimulated only through patent-protected mark-ups that exclude poor patients during the patent period. But various plausible alternative mechanisms, designed to overcome existing access problems, have been proposed over the last decade. 9 Here we discuss one such mechanism, the Health Impact Fund (HIF), which would complement the existing system by offering innovators the option to register a new medicine or, under certain conditions, a traditional medicine or a new use of an existing medicine. By registering a product, the innovator would undertake to make it available globally, during its first ten years on the market, at no more than the lowest feasible cost of production and distribution. The innovator would further commit to allowing, at no charge, generic production and distribution of the product after this decade has ended. In exchange, the registrant would during this decade receive annual reward payments based on its product's health impact.
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The HIF is potentially beneficial on three fronts. First, it would foster development of important medicines against diseases concentrated among the poor. Pharmaceutical innovators are now neglecting such diseases because they have no realistic hope of recovering their R&D costs from sales to the poor (Moran et al. 2009 ). Second, the HIF would at any time support availability of a set of vital new medicines worldwide at very low prices. Third, the HIF would motivate registrants to ensure that their products are widely available, perhaps even below the price ceiling, and that they are competently prescribed and optimally used.
Each reward payment would be part of a large annual pay-out, with every registered product receiving a share equal to its share of the assessed health impact of all HIFregistered products in the relevant year.
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The HIF's annual reward pools might initially be set at $6 billion -about 0.03 percent of the gross national products of China plus the US or Brazil plus the EU. If HIF-rewarded innovations were funded through taxes, affluent people would bear most of the cost and poor people would contribute little or nothing -just like under the current system. The key difference is Registrants would be rewarded not for merely selling their products, but for making them effective toward improving global health.
9 Most of the more plausible proposals are described and discussed in the work of the WHO Consultative Expert Working Group on Research and Development (CEWG), available at www.who.int/phi/news/cewg_2011/en/index.html. 10 Measured in quality-adjusted life years saved. The QALY metric has been refined over the last 20 years and is already widely used, e.g., by public and private insurers deciding which new drugs to cover (Phillips 2009 ). 11 A registrant would want to offer its product below cost if and insofar as it expects its additional health impact rewards due to reaching additional patients to be larger than its loss on the sales price. A registrant would want to promote the wide and proper use of its product, especially by those who can benefit most from it, if and insofar as the additional health impact rewards due to such efforts exceed their costs.
that, instead of being excluded by large mark-ups, poor patients would gain access to HIF-rewarded medicines at prices that cover the cost of manufacture and distribution. By funding pharmaceutical innovation in this new way, affluent populations stand to benefit from lower drug prices (directly and through lower expenses for insurance, national health systems, and foreign aid), from better marketing of drugs for optimal health impact, from faster economic growth in poorer countries and from reduced transmission of infectious diseases to richer countries (Section 2).
By funding the HIF, affluent populations would also reduce their role in a grievous injustice.
The HIF model shows clearly that the development of new medicines can be incentivized in a way that allows poor patients immediate access at the cost of manufacture and distribution. In view of this possibility, it is wrong for the affluent to choose to incentivize the development of important new medicines for themselves through the worldwide enforcement of temporary monopolies that prevent generic manufacturers from supplying cheap copies to poor patients.
Global Institutions and Social Justice
We first show that there are vast income inequalities across the world. We then illustrate how supranational institutional arrangements may be aggravating inequality and poverty worldwide (Pogge 2004) . The final subsection sets out the tenets of a case for global health interventions from the standpoint of moral and political philosophy.
Poverty and inequality at birth
Some defenders of TRIPS contend that it is natural and not unfair that affluent people have all kinds of expensive things that poor people cannot afford to buy. This contention assumes an acceptable distribution of income and wealth. But are existing economic inequalities fair? They have accumulated over a history of colonial conquest, enslavement, exploitation and genocide. Over 80% of income variability worldwide is explained by a person's country and socio-economic class at birth (Milanovic 2009 
Global factors in the perpetuation of poverty and inequality
With the losses most severe in the poorest quarter, income has become more polarized: across seventeen years, the ratio between the average income in the richest ventile and that in the poorest quarter has skyrocketed from 185 to 297. Today, the poorer two-thirds of humanity have merely 6% of global household income and 4% of global private wealth (Sharrocks et al. 2010, Davies and Schmid 2010) .
A familiar argument against foreign aid or other international interventions is that they do not reach the target population on account of developing-country governments being corrupt (e.g., Fourth, affluent countries and their firms often buy natural resources from the rulers of less-developed countries without regard for how such rulers came to or exercise power. In many cases, this amounts to collaboration in the theft of these resources from their owners, the country's people. It also enriches their oppressors, thereby entrenching the oppression: tyrants sell their victims' natural resources and use the proceeds to buy the weapons they need to keep themselves in power (Pogge 2008 , Wenar 2008 ).
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13 Kar and Curcio 2001, pp. 3, 21, 37 . This outflow is over four times larger than all official development assistance which, during this period, averaged $83 billion annually, of which only $8 billion was allocated to "basic social services." United Nations, MDG Indicators, http://unstats.un.org/unsd/mdg/Search.aspx?q=bss%20oda.
Because production is much more labor-intensive in poor than in affluent countries, such protectionist measures tend to destroy many more jobs in poor than they create in more affluent countries.
The justice case
The core function of institutional arrangements -of the rules and practices structuring a national society or other social system -is to protect the freedom and well-being of the individuals whose lives are governed or profoundly affected by them. Physical and mental health is fundamental to both freedom and well-being. Institutional arrangements ought then to be designed and (if needed) reformed so as to enable those whose lives they profoundly affect to lead full and healthy lives.
This widely accepted thought is often connected with the value of solidarity (or risk-sharing).
All human beings are vulnerable to various serious threats to their physical and mental health, and we can cope much better with these threats when we pool some of our resources. To be sure, participation in a scheme of organized solidarity will not be equally advantageous for all, even ex ante.
Some will not be able to contribute a lot to the pool and some will foreseeably place greater burdens on it; and such people are then likely to receive a share of the scheme's benefits that is larger than their share in the scheme's cost. But solidarity is a strong moral reason to include and to assist the more vulnerable among us.
While we endorse this call for solidarity, both within and beyond national borders, we also recognize that, on its own, it conveys an incomplete and potentially misleading picture. Institutional arrangements not merely address some of the health problems and vulnerabilities that individuals bring with them into society. They also shape these people and their environments, thereby profoundly affecting what health problems and vulnerabilities people face in the first place. Social institutions influence access to nutrients and patterns of environmental hazards, for example, and the resulting childhood exposure to malnutrition or lead pollution can have serious effects on persons' health needs for the rest of their lives (Section 2). Similarly consequential for health are a society's choices about public hygiene and sanitation, access to health knowledge, traffic rules, law enforcement, political competition and protections against domestic and employer abuse. Persons whose health has been undermined by avoidable defects in any of these social factors can plead for solidarity, of course. But they can also invoke the more stringent value of justice.
One might say in response that, just like health care, the social determinants of health fall exclusively under the value of solidarity, which is lacking in a social order under which people are avoidably left to starve or must find their own way of protecting themselves from assault. We hold that such a social order is also unjust. Those upholding it are not merely insufficiently attentive to the needs of some of those on whom they impose it, but can also be said to be actively harming them. To be sure, one is not harming unemployed persons when one fails to provide them with food they need to survive. But one is harming when one imposes institutional arrangements under which foreseeably some are avoidably unable to meet their basic needs. The latter formulation may need some explication. As the word "standard" indicates, it is not here postulated that each person has a claim to whatever resources may be needed to maintain her in, or restore her to, good health. The assertion is rather that each is entitled to enjoy whatever plausible overall standard can reasonably be achieved for all. Here three limiting considerations come into play. First, for some specific piece of health protection (a safe water supply, say, or some medical procedure) to count as "attainable," it must be achievable for all and not merely for some.
Second, for a specific piece of health protection to count as achievable for all, it must be achievable not merely by itself, but as part of a plausible package of health protections that can be simultaneously achieved for all. This is why we speak of a plausible overall standard, one that covers a set of diverse health protections intelligently selected in light of a society's capacities and all relevant costs, opportunity costs, synergies, complementarities, etc. Third, there should be no requirement to assign absolute priority to health over everything else (such as culture, education, and leisure time).
Even if a higher standard of health could be attained by eradicating all wild animals, for example, a society may judge this cost to be unreasonably high relative to the health gains attainable through it.
Some still claim supranational arrangements (such as TRIPS) as a morality-free zone in which the concept of justice has no application (Nagel 2005) . But, on reflection, this claim is hard to justify.
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16 For further compelling critique of Nagel's view, see Cohen and Sabel 2006. If it is unjust for each of a group of governments to impose certain rules upon its own country's population, then it must also be unjust for this same group of governments to impose the same rules upon all their countries' populations pursuant to some international agreement.
The upholding of any institutional order involves a substantial element of coercion, which is morally justifiable only if the institutional order imposed meets certain requirements of social justice.
What these requirements are is controversial, especially in the case of supranational institutional arrangements that govern people committed to a wide diversity of moral conceptions. But it is fairly uncontroversial that institutional arrangements must at least be human-rights compliant, that is, must not foreseeably give rise to substantial and reasonably avoidable human rights deficits.
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Insisting on this minimal condition is especially important in regard to supranational rules which are not formulated through the kind of transparent, democratic procedures that characterize national law-making in the countries that have reached a basic level of domestic justice. Rather, supranational rules mostly emerge through intergovernmental negotiations that effectively exclude the general public and even the majority of weaker governments. Only a small number of "players" can exert real influence: powerful organizations, prominently including large multinational corporations and banks, very rich individuals and ruling "elites" of the most powerful developing countries. They can reap huge gains from favorable supranational rules and can therefore afford to make large investments into acquiring the necessary expertise, forming alliances and lobbying the stronger (G20) governments that dominate supranational rule-making. Ordinary citizens, by contrast, typically find it prohibitively expensive to acquire the necessary expertise and to form alliances that are large enough to rival corporate influence. In the absence of global democratic institutions, the shift toward global governance sidelines the vast majority of human beings, while greatly enhancing the rule-shaping powers of a tiny minority of those who are already the richest and most powerful. Their interests are diverse, and some elite players fail in their efforts to shape in their favor the rules that stand to impact them the most. Yet, the rules do get captured by some elite players and, as a group, they consequently grow their share of global wealth and expand their advantage over the rest of humankind. This, in turn, further increases their capacity to influence the design and application of the rules in their own favor and, unintentionally but no less inexorably, contributes to keeping the poorer section of humankind in dire poverty.
Conclusions
In poor countries infectious diseases cause high levels of morbidity and mortality that are avoidable at low cost. While recognizing local barriers to progress on the demand and supply side, we have underlined the role of internationally imposed constraints on progress. We have indicated that interventions targeted at early-childhood health may be among the best investments in poor countries -they are less easily appropriated than cash transfers, directly improve quality of life, generate education and income externalities, are likely to be cost-effective and have built-in tendencies towards being self-sustaining. These factors strengthen the political case for intervening now. Against this backdrop, we have discussed ethical and pragmatic reasons for richer countries to undertake internationally coordinated commitments to tackle disease in poorer countries, focusing attention upon reforming the way pharmaceutical innovation is rewarded.
The present TRIPS system reflects the prejudice that innovation must be rewarded through large mark-ups, at the expense of access by the poor who, if they survive, gain access after patent expiration. We have made the following essential arguments against this regime. First, by an eclectic set of widely recognized ethical principles, including libertarian ones at one extreme, the current regime is unfair. Second, it is also unnecessary insofar as there is an alternative feasible regime that would incentivize pharmaceutical R&D without aggravating health (and thereby economic) inequalities. Third, we have highlighted evidence from epidemiology and economics suggesting that investment in disease mitigation among the poor today is economically wise and, with a lag, likely to pay for itself. Moreover, richer countries and richer people in poor countries have an incentive to contribute to making this investment because improving the health of the poor generates positive externalities for the rich.
A common depiction of the problems of ill health and poverty in poor countries is that they are complex and insurmountable. Furthermore, health problems are often shown to be demanddriven, for example, people may not have relevant information or sufficient education to process new information, leading to low uptake of publicly provided health goods (e.g., Banerjee et al. 2011 ).
While this is valid, the existence of one sort of barrier does not justify imposing another barrier to progress. Economists have documented the relevance of market, government and political failures in contributing to incentive problems and other obstacles in the delivery of public health. We add that there is failure of the international political economy of global health marked by information constraints, commitment problems, poor representation of constituent preferences and limited accountability.
